Ionis Pharma

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ionis Pharma excels in Q4, eyes revenue growth and strategic expansion

Ionis Pharma's Q4 2022 performance reflects strong revenue growth, pipeline advancements, and strategic positioning for future success.
The company's focus on commercialization, R&D innovation, and financial discipline underscores its resilience and growth potential in the biopharmaceutical industry.
While facing challenges in operational costs and market dynamics, Ionis Pharma remains well-positioned to leverage opportunities in genetic medicines and revenue diversification.

Ionis Pharma reports strong Q1 earnings and outlines growth plans

Ionis Pharma's Q1 performance solid with revenue growth and strong cash position
Company's strengths lie in FDA approvals, positive study data, and pipeline progress
Challenges include rising expenses, competitive landscape, and pricing strategies
Opportunities seen in PV market, HAE program, and growth prospects in coming years

Ionis Pharma reports strong Q2 performance and prepares for launches

Ionis Pharma's Q2 2023 earnings call highlighted strong performance, with revenue growth, key milestones in pipeline advancements, and a solid financial position.
The company faces challenges in study readout timing, competitive landscape changes, and market competition but has opportunities for growth through successful enrollment and product launches.
Key strengths include successful collaborations, encouraging interim results for SPINRAZA, and preparations for upcoming product launches, positioning Ionis Pharma for future success.
Overall, Ionis Pharma remains focused on advancing its pipeline, meeting financial guidance, and leveraging opportunities for growth in the biopharmaceutical market.

Ionis Pharma reports strong Q3 performance and neurology pipeline advancements

Ionis Pharma's Q3 earnings call highlighted strong performance, strategic successes, and advancements in the neurology pipeline.
The company faces challenges in a competitive landscape but has strengths in partnerships, innovation, and pricing strategies.
Opportunities lie in upcoming data releases, potential treatment benefits, and market differentiation strategies.
Overall, Ionis Pharma remains focused on delivering value to patients and investors through its innovative therapeutics.

Ionis Pharma reports robust 2023 results and eyes growth opportunities

Ionis Pharma's strong financial performance in 2023 and projected revenue for 2024 reflect a promising outlook for the company's growth and commercialization efforts.
While facing challenges in patient eligibility and treatment optimization, Ionis Pharma's focus on pipeline advancement and strategic investments positions it well for future success.
The company's emphasis on neurological disease platforms, upcoming data readouts, and collaborations present significant opportunities for expansion and innovation.

Ionis Pharma reports robust Q1 performance and advances key treatments

Ionis Pharma's Q1 2024 performance reflects strong revenue growth and progress in key pipeline programs, positioning the company for future success and sustained positive cash flow.
With a focus on strategic investments, innovative treatments, and upcoming data presentations, Ionis demonstrates a commitment to driving growth and addressing unmet medical needs.
While facing challenges in managing expenses and securing regulatory approvals, Ionis Pharma remains well-positioned to capitalize on market opportunities and partnerships for continued development and commercial success.

Ionis Pharma reports solid Q2 earnings, eyes growth through innovation

Ionis Pharma's Q2 performance reflects steady revenue growth and positive feedback on recent launches and ongoing trials.
The company's strengths lie in its innovative therapies, strong clinical profile, and strategic focus on expanding the product portfolio.
Challenges include sustaining momentum in competitive markets and ensuring successful commercialization of upcoming products.
Opportunities exist in market expansion, new patient segments, partnerships for pipeline growth, and investments in next-gen technologies.

Ionis Pharma reports strong pipeline progress and commercial success

Ionis Pharma's Q3 earnings call highlighted positive pipeline developments, successful product launches, and sustained investment for growth.
While facing challenges in competitive positioning and data availability, Ionis Pharma remains focused on leveraging opportunities in patient engagement and market expansion.
Overall, Ionis Pharma's performance reflects a promising outlook with strong potential for future growth and market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals said on Tuesday its experimental drug met main goal in a late-stage trial testing it as a treatment for a rare genetic disorder known as familial chylomicronemia syndrome.

Ionis Pharma's genetic disorder drug meets main goal in late-stage study

Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent  Olezarsen demonstrated a favorable safety and tolerability profile Ionis plans to file a New Drug Application with U.S. FDA in preparation for first potential independent launch Phase 3 studies continue evaluating olezarsen in broader patient population with severe hypertriglyceridemia (SHTG)  Ionis to host webcast today at 11 a.m. ET CARLSBAD, Calif.

Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome

Goldman Sachs

Eli Lilly

Pinduoduo Inc - ADR

Peloton

T-Mobile US

Toast

While many retail investors are keen to discover which securities the big market players are snapping up, sometimes it's more telling to zero in on the stocks institutional traders are selling. Why? Because trading, for all its analytics, can be an emotional rollercoaster.

The 7 Most Hated Stocks by Institutional Traders

Ionis Innovation Day: Discovering, Developing and Delivering Transformational Medicines Presentations by key members of Ionis leadership and notable KOLs CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host an investor and analyst day on Wednesday, October 4.

Ionis to host investor and analyst day event

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?

Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?

Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially approved drugs for various diseases. Ionis has a strong pipeline of late-stage candidates, including Eplontersen, Olezarsen, and Donidalorsen, with the potential for significant market opportunities.

Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers

Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates.

Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)

Ionis Pharmaceuticals (IONS) came out with quarterly loss of $0.60 per share, beating the Zacks Consensus Estimate of a loss of $0.94 per share. This compares to loss of $0.74 per share a year ago.

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2023 Earnings Conference Call August 9, 2023 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - CEO Richard Geary - Chief Development Officer Beth Hougen - CFO Onaiza Cadoret - Chief Global Product Strategy & Operations Officer Eugene Schneider - Chief Clinical Development Officer Eric Swayze - EVP, Research Conference Call Participants Myles Minter - William Blair Robert Finke - Guggenheim Partners Kostas Biliouris - BMO Capital Markets Mike Ulz - Morgan Stanley Yanan Zhu - Wells Fargo David Lebowitz - Citigroup Inc. Allison Bratzel - Piper Sandler Paul Matteis - Stifel Yaron Werber - TD Cowen Luca Issi - RBC Capital Markets Yale Jen - Laidlaw & Company Joseph Stringer - Needham & Company Operator Good morning, and welcome to Ionis' Second Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded.

Ionis Pharmaceuticals, Inc. (IONS) Q2 2023 Earnings Call Transcript

Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to Say

Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of a loss of $0.94 per share. This compares to loss of $0.74 per share a year ago.

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates

Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks; December 22, 2023 PDUFA date Completed enrollment in donidalorsen OASIS-HAE study and eplontersen CARDIO-TTRansform ATTR-CM study keeping Phase 3 data readouts on track On track to achieve 2023 financial guidance CARLSBAD, Calif. , Aug. 9, 2023 /PRNewswire/ -- – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2023.

Ionis reports second quarter 2023 financial results

Builds on existing collaboration with Novartis for pelacarsen, which is currently being evaluated in a Phase 3 cardiovascular outcome study with data expected in 2025 Ionis' new and advanced technologies will be used to create next generation compound targeting Lp(a) Ionis will receive a $60 million upfront payment CARLSBAD, Calif. , Aug. 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered a collaboration and license agreement with Novartis for the discovery, development and commercialization of a novel medicine for patients with lipoprotein(a), or Lp(a)-driven cardiovascular disease (CVD).

Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease

CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events.

Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy

Companies jointly developing and commercializing eplontersen in the U.S.  AstraZeneca adds Latin America as part of its exclusive rights for rest of world CARLSBAD, Calif. , July 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America.

Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America

Webcast scheduled for Wednesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Ionis to hold second quarter 2023 financial results webcast

Alnylam Pharmaceuticals

BridgeBio Pharma Inc

BridgeBio landed a "best-case scenario" for its heart-disease drug on Monday, helping BBIO stock and shares of competitors to rocket.

BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine Signs Multi-Target Partnership with Ionis Pharmaceuticals.

Scipher Medicine Signs Multi-Target Partnership with Ionis

Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study

Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeks Data further strengthen eplontersen's differentiated profile, positioning it to be an important potential treatment for patients with ATTRv-PN CARLSBAD, Calif. , July 10, 2023  /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced positive topline, 85-week data from the Phase 3 NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

CARLSBAD, Calif. , July 5, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023.

Ionis to present at upcoming investor conference

Interim results from RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)  CARLSBAD, Calif. , June 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® (nusinersen) in infants and toddlers living with spinal muscular atrophy (SMA).

New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy

Ionis Pharmaceuticals' phase 2 study showed that patients treated with donidalorsen through week 17 achieved a 90% reduction in hereditary angioedema attack compared to placebo; the second dose brought a 97% reduction. Clinical trial results from the phase 3 OASIS-HAE study, using donidalorsen for the prevention of hereditary angioedema attacks, are expected to be released in the 1st half of 2024. The global hereditary angioedema treatment market size is projected to reach $6.53 billion by the end of 2025.

Ionis: Potential Advancement Into HAE Space Makes This A Must Watch

CARLSBAD, Calif. , June 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

News for Ionis Pharma Stock (IONS)